Literature DB >> 29990628

Threatened preterm labour: Women's experiences of risk and care management: A qualitative study.

Jenny Carter1, Rachel M Tribe2, Andrew H Shennan2, Jane Sandall2.   

Abstract

BACKGROUND: Preterm birth is a major cause of neonatal death and severe morbidity, so pregnant women experiencing symptoms of threatened preterm labour may be very anxious. The risk assessment and management that follows recognition of threatened preterm labour has the potential to either increase or decrease this anxiety. The aim of this study was to explore women's experience of threatened preterm labour, risk assessment and management in order to identify potential improvements in practice.
DESIGN: One-to-one semi-structured interviews with 19 women who experienced assessment for threatened preterm labour took place between March 2015 and January 2017. A purposive sample approach was employed to ensure participants from different risk and demographic backgrounds were recruited at an inner city UK NHS hospital. Interviews were recorded and transcribed. Data was managed with NVivo software and analysed using the Framework Approach. A public and patient involvement panel contributed to the design, analysis and interpretation of the findings.
FINDINGS: Data saturation was achieved after 19 interviews. 11 women were low risk and 8 were high risk for preterm birth. All high risk women had experience of being supported by a specialist preterm team. Four main themes emerged: (i) coping with uncertainty; (ii) dealing with conflicts; (iii) aspects of care and (iv) interactions with professionals. Both low and high risk women experiencing TPTL struggle to cope with the uncertainty of this unpredictable state. The healthcare management they receive can both help and hinder their ability to cope with this extremely stressful experience. High risk women were less likely to receive conflicting advice. KEY CONCLUSIONS AND IMPLICATIONS FOR PRACTICE: Clinicians should acknowledge uncertainty, minimize conflicting information and advice, and promote continuity of care models for all women, including those attending high risk clinics and in the ward environment.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Experience; Preterm; Threatened preterm labour

Mesh:

Year:  2018        PMID: 29990628     DOI: 10.1016/j.midw.2018.06.001

Source DB:  PubMed          Journal:  Midwifery        ISSN: 0266-6138            Impact factor:   2.372


  5 in total

1.  Development and validation of a transcriptomic signature-based model as the predictive, preventive, and personalized medical strategy for preterm birth within 7 days in threatened preterm labor women.

Authors:  Yuxin Ran; Jie He; Wei Peng; Zheng Liu; Youwen Mei; Yunqian Zhou; Nanlin Yin; Hongbo Qi
Journal:  EPMA J       Date:  2022-01-18       Impact factor: 6.543

2.  Early detection of mental illness for women suffering high-risk pregnancies: an explorative study on self-perceived burden during pregnancy and early postpartum depressive symptoms among Chinese women hospitalized with threatened preterm labour.

Authors:  Qianqian Ni; Guizhi Cheng; An Chen; Seppo Heinonen
Journal:  BMC Psychiatry       Date:  2020-05-20       Impact factor: 3.630

3.  Efficacy of allylestrenol combined with ritodrine on threatened premature labor and its influence on inflammatory factors in peripheral blood.

Authors:  Qing Li; Chunhua Li; Hongmei Jin
Journal:  Exp Ther Med       Date:  2019-12-03       Impact factor: 2.447

4.  Protocol for the IMPART study: IMplementation of the preterm birth surveillance PAthway - a RealisT evaluation.

Authors:  Naomi Carlisle; Sonia Michelle Dalkin; Andrew H Shennan; Jane Sandall
Journal:  BMJ Open       Date:  2022-03-29       Impact factor: 2.692

5.  Getting a grip in the middle of chaos: Preparing for preterm parenthood during a high-risk pregnancy - Parental experiences and needs.

Authors:  Kiki Ruhe; Agnes van den Hoogen; Tinka Bröring-Starre; Joke M Wielenga; Mirjam M van Weissenbruch
Journal:  Acta Paediatr       Date:  2022-04-22       Impact factor: 4.056

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.